The instrument is fully integrated with Lonza’s latest WinKQCLSoftware to enable data integrity compliance, streamline training, and reduce validation burden
Acuitas Therapeutics' LNP technology will support Bayer’s in vivo gene editing and protein replacement programs with the goal of specifically delivering RNA payloads to the desired target organ, the liver.
Injectafer is now the first and only intravenous (IV) iron replacement therapy indicated for adult patients with heart failure who have iron deficiency
First clinical trial reporting results of an mRNA therapeutic for intracellular protein replacement
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
SVB Financial Group and its subsidiaries were involved in over $1.4 billion in total venture financing raised from 2010 to 2022 for drug development
Cooperative agreement with U.S. Government to advance U.S. biopharma industry and ensure pandemic preparedness
Expands robotics to 20+ specialities
Patients will no longer need to travel abroad for treatment of acute cardiac diseases
Subscribe To Our Newsletter & Stay Updated